Newest first. 5.2k questions across 107 tags.
The specifics, since they change the answer: STEP 3 · early satiety. I want to understand what this actually establishes, as opposed to what it is being used to…
For reference: VendorInvestigate · PeptideMeter · mazdutide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments…
For reference: GGPeps · ecnoglutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
What I am working with: three weeks · mazdutide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have…
Stated plainly: ERP · a GLP-1 receptor agonist. This is not behaving the way I expected and I want to understand the discrepancy before I act on it. I have…
The method section is present, which is unusual enough that I want to make use of it. I would like to set this up properly once, rather than adjust it repeatedly. My…
Setup, so nobody has to ask: 99.1% · mazdutide · QST. I would like to set this up properly once, rather than adjust it repeatedly. My budget is real but not tight,…
Stated plainly: ERP · GL Biochem (Shanghai). Both of these get recommended confidently by different people, which suggests neither is obviously right. My constraints…
What I have: 97.6% · Janoshik · 98.4% · Medutest. I have used one of these for a while and I am considering switching, which requires a reason. What I care about is…
What I have: a GLP-1 receptor agonist · 10 mg. I can do the algebra. I am not confident about the conversion factors. If there is a standard way to lay this out, I…
What I have: 97.1% · lot-specific certificate. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
Details up front: FLOW · constipation. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
Numbers first: TRIUMPH-1 · early satiety · 50 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear…
Numbers first: a GLP-1 receptor agonist · PIONEER-1. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring…
Numbers first: SWB · Shanghai · Norway. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me which work…
What I have: SURMOUNT-1 · nausea. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
Numbers first: 8 mg · orforglipron. I can do the algebra. I am not confident about the conversion factors. If there is a standard way to lay this out, I would rather…
Numbers first: 95.2% · orforglipron · SSA. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me which work…
I am comparing a supplier certificate against an independent result on the same lot. This is one of those things that everyone repeats and nobody derives. This…
Conditions: survodutide · seven days. I want the working, not the result — I need to be able to redo it with different numbers. I care about the precision as well as…
The case in front of me: survodutide · a C4 column · mazdutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like…
Conditions: Homopeptide · Wuhan Wansheng Biotechnology. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know…
Concretely: semaglutide · a C4 column · liraglutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know…
Concretely: Xianning · Norway. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change the…